rothall.blogg.se

3 Moreover, the roles of ER/PR in predicting response to hormonal therapy are well established.

1, 2 Patients with hormone receptor-negative disease have a higher risk of mortality compared with those with hormone receptor-positive disease. © 2010 American Cancer Society.Įstrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer patients. In contrast, the authors found no evidence of an increased rate of DM in these patients with favorable disease stage. Patients with T1a,bN0 breast cancer with only 1 positive hormone receptor have increased rates of LR recurrence compared with patients with ER +/PR + disease, although this difference may be reduced or eliminated with systemic treatment. On multivariate analysis, 1 positive receptor predicted for LR recurrence in the overall group (hazard ratio, 2.81 95% confidence interval, 1.06-7.48 P =. 046), but not in patients who received hormonal therapy ( P =. One positive receptor predicted for LR recurrence in patients who did not receive hormonal therapy ( P =. There was no difference between the 2 groups in the rates of distant metastasis (DM) ( P =. LR recurrence rates were higher in patients with 1 receptor positive compared with ER +/PR + (7-year rate: 8.8% vs 2.5%, P =.

They compared clinical outcomes of the 479 patients with ER +/PR + disease to the 156 patients with ER +/PR − or ER −/PR +disease. The authors retrospectively reviewed records of 635 patients with T1a,bN0 disease who received definitive treatment at their institution between 19 and had archival tissue blocks for prospective assessment of ER/PR expression. Few data correlate these biomarkers with locoregional (LR) recurrence. However, some data suggest that patients with ER +/PR − or ER −/PR + tumors may have worse outcomes than those with ER +/PR + tumors. Patients with tumors positive for either receptor are generally considered hormone receptor-positive for treatment decisions.

Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer.